

A child and a young girl are running together, holding a flag on a string. The child is on the left, and the girl is on the right. The flag is white and is being held up by the girl. The background is a light green color.

CureSearch

Children's Oncology Group

Long-Term Follow-Up Guidelines

for Survivors of Childhood, Adolescent,
and Young Adult Cancers

Version 3.0 – October 2008

Patient-Specific Guideline Identification Tool

Copyright 2008 © Children's Oncology Group
All rights reserved worldwide

Instructions for Using the Patient-Specific Guideline Identification Tool

To determine *Long-Term Follow-Up Guideline* sections relevant to an individual patient:

1. Place a checkmark in the “Mark if Patient Received” or “Mark All that Apply” column for each chemotherapy agent, radiation field, surgery, or other therapeutic modality that the patient received.
2. Place a checkmark in the “Mark as Indicated” column for all cancer screening guidelines that are applicable to this patient based on age, gender, and indicated conditions.
3. Compile a list of all section numbers generated during steps 1 and 2. Include the following sections as applicable:
 - Sections 1-2 Applicable to all patients
 - Section 3 Patients diagnosed before 1972
 - Section 4 Patients diagnosed before 1993
 - Section 5 Patients diagnosed between 1977 and 1985
 - Section 6 All patients who received chemotherapy
 - Sections 92-97 All patients who underwent hematopoietic cell transplant
 - Sections 98-106 Patients with history of chronic graft-vs-host (cGVHD) disease*
 - *Section 103 is for patients with active cGVHD only
 - *Section 105 is for females only
 - Section 146 Applicable to all patients

You now have a list of all guideline sections potentially applicable to this patient.

4. For patients who received radiation for which a minimum dose specification is indicated, follow the instructions for “Determining Applicability of Radiation Sections for Specific Patients Based on Exposure” (see page 47 of Guidelines or page 2 of *Radiation Reference Guide*). Delete from your list those radiation section(s) for which this patient did not receive the minimum radiation exposure at which the section(s) become applicable.
5. You now have a finalized list of all guideline sections applicable to this patient.

Patient-Specific Guideline Identification Tool
(Applicable Guideline Sections indicated in Bold/Red; M=Male; F=Female)

Name: _____	Sex: M/F	Date of Birth: _____
Cancer Diagnosis: _____	Date of Diagnosis: _____	End Therapy Date: _____
<input checked="" type="checkbox"/> Sections 1 & 2 applicable to all patients	Prior to 1972: <input type="checkbox"/> Section 3 Prior to 1993: <input type="checkbox"/> Section 4 1977 - 1985: <input type="checkbox"/> Section 5	LTFU guidelines are applicable to patients who are ≥2 years following completion of cancer therapy

CHEMOTHERAPY: Yes No **If yes:** **Section 6** and applicable guidelines for specific chemotherapy agents below

Chemotherapy Agent (mark if patient received)	Applicable guideline sections
Asparaginase	Section 34
Bleomycin	Section 29
Busulfan	Sections 7M/F, 8, 9, 10
Carboplatin – all doses	Sections 7M/F, 8, 15, 16, 17
– myeloablative dose	See also: Section 14 <small>Note: Myeloablative dose = conditioning for HCT</small>
Carmustine	Sections 7M/F, 8, 9
Chlorambucil	Sections 7M/F, 8
Cisplatin	Sections 7M/F, 8, 14, 15, 16, 17
Cyclophosphamide	Sections 7M/F, 8, 11, 12
Cytarabine: SQ, IT, IO, low-dose IV	Section 20 <small>Note: Low-dose IV = all single doses < 1000 mg/m²</small>
Cytarabine: High-dose IV	Sections 18, 19 <small>Note: High-dose IV = any single dose ≥1000 mg/m²</small>
Dacarbazine	Sections 7M/F, 8
Dactinomycin	Section 30
Daunorubicin* Cumulative dose: _____ mg/m ² Age at first dose: _____	Sections 27, 28M/F Cumulative dose x 0.833 = <input type="text"/> mg/m ² = doxorubicin isotoxic dose
Dexamethasone	Sections 31, 32, 33
Doxorubicin* Cumulative dose: _____ mg/m ² Age at first dose: _____	Sections 27, 28M/F Cumulative dose x 1 = <input type="text"/> mg/m ² = doxorubicin isotoxic dose
Epirubicin* Cumulative dose: _____ mg/m ² Age at first dose: _____	Sections 27, 28M/F Cumulative dose x 0.67 = <input type="text"/> mg/m ² = doxorubicin isotoxic dose
Etoposide (VP-16)	Section 37
Idarubicin* Cumulative dose: _____ mg/m ² Age at first dose: _____	Sections 27, 28M/F Cumulative dose x 5 = <input type="text"/> mg/m ² = doxorubicin isotoxic dose
Ifosfamide	Sections 7M/F, 8, 11, 13
Lomustine	Sections 7M/F, 8, 9
Mechlorethamine	Sections 7M/F, 8
Melphalan	Sections 7M/F, 8
Mercaptopurine (6-MP)	Section 21

*Use formulas below to convert to doxorubicin isotoxic equivalents prior to calculating total cumulative anthracycline dose:
Doxorubicin – multiply total dose x 1 **Daunorubicin** – multiply total dose x 0.833 **Epirubicin** - multiply total dose x 0.67
Idarubicin - multiply total dose x 5 **Mitoxantrone** - multiply total dose x 4
Note: There is a paucity of literature to support isotoxic dose conversion; however, the above conversion factors may be used for convenience in order to gauge screening frequency. Clinical judgment should ultimately be used to determine indicated screening for individual patients.

Chemotherapy Agent (cont) (mark if patient received)	Applicable guideline sections
Methotrexate: PO, IM, low and high-dose IV	Sections 22, 23, 24
Methotrexate: High-dose IV, IT, IO	Sections 25, 26 Note: High-dose IV = any single dose ≥ 1000 mg/m²
Mitoxantrone* (see footnote on previous page) Cumulative dose: _____ mg/m ² Age at first dose: _____	Sections 27, 28M/F Cumulative dose x 4 = _____ mg/m² = doxorubicin isotoxic dose
Prednisone	Sections 31, 32, 33
Procarbazine	Sections 7M/F, 8
Temozolomide	Sections 7M/F, 8
Teniposide (VM-26)	Section 37
Thioguanine (6-TG)	Section 21
Thiotepa	Sections 7M/F, 8
Vinblastine	Sections 35, 36
Vincristine	Sections 35, 36

Total anthracycline cumulative dose (doxorubicin isotoxic equivalent) = _____ mg/m²
(Instructions: Add all anthracycline doses from boxes in above table to obtain total cumulative dose)
 Note: For doses in mg/kg, multiply by 30 to obtain equivalent dosing in mg/m²

RADIATION: Yes No *If yes, include applicable guidelines based on exposure to specific radiation field(s) (see instructions[§])*

§INSTRUCTIONS FOR RADIATION SECTIONS:

DETERMINING APPLICABILITY OF GUIDELINE SECTION BASED ON MINIMUM RADIATION DOSE SPECIFICATIONS:

Sections with minimum dose specifications are applicable to a patient only if:

1. Patient received radiation to any field(s) relevant to the particular guideline section at \geq the specified minimum dose[†]

OR

2. Patient received a combination of radiation to any relevant field(s)[†] **plus** relevant spinal radiation[†] **and/or** TBI, the sum of which is \geq the specified minimum dose[§]

[†]Total dose to each field should include boost dose, if given. If patient received radiation to more than one field relevant to a particular guideline section during a single planned course of radiation treatment (excluding spinal radiation and TBI), the field that received the largest radiation dose should be used in making the determination as to the applicability of the indicated guideline section(s). *Exception: If patient received radiation to the same field at different times (e.g., at time of diagnosis AND at relapse), these doses should be added together when considering the applicability of the indicated guideline section.*

[‡]Use the largest dose of radiation delivered to the spinal field(s) specified in the guideline section

[§]Whole lung radiation, if given, should be included in minimum dose calculations for Sections 65, 66, 67, 68, 73, and 91.

See Appendix I – “Radiation Reference Guide” – for examples.

SELECTING APPLICABLE GUIDELINE RADIATION SECTIONS BASED ON RADIATION EXPOSURE:

- Select all sections listed under “any dose” for each applicable radiation exposure
- Refer to the “Radiation Reference Guide” in Appendix I to determine which, if any, of the sections with minimum dose specifications are applicable to each particular patient based on their exposures
- For examples of radiation dose calculations, see pages 3 – 5 of the “Radiation Reference Guide”

Radiation by field [§] (mark all that apply)		Applicable guideline sections	
ALL RADIATION FIELDS:			
All radiation fields including TBI	Any dose	Sections 38, 39	
All radiation fields <u>except</u> TBI	Any dose	Sections 40, 41	
TOTAL BODY IRRADIATION (TBI):			
Total body irradiation (TBI)	Any dose	Sections 38, 39, 42, 43, 44, 49, 50, 56, 60, 62, 63, 64, 68F[‡], 69F, 70, 71M/F, 78[‡], 79, 83F, 84F, 86M, 88[‡] [‡]Screening <i>may</i> be indicated; refer to Info Link in this section	
HEAD/BRAIN:			
Cranial [Any field involving the cranium/head, brain, and/or face]	Any dose	Sections 42, 43, 44, 46, 47, 48, 49, 50, 51M/F, 56, 59, 60, 62, 63, 64	
	Minimum dose specifications apply	See Pages 11-13 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 45, 52M/F, 53, 54 M/F, 55, 57, 58, 61, 65, 66	
Orbital/Eye	Any dose	Sections 42, 46, 47, 48, 49, 50, 51M/F, 56	
	Minimum dose specifications apply	See Page 11 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 45, 52M/F, 53, 54M/F, 55, 57	
Ear/Infratemporal	Any dose	Sections 42, 43, 44, 46, 47, 48, 49, 50, 51M/F	
	Minimum dose specifications apply	See Page 11 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 45, 52M/F, 53, 54M/F, 55, 58	
Nasopharyngeal	Any dose	Sections 42, 46, 47, 48, 49, 50, 51M/F, 59, 60, 62, 63, 64	
	Minimum dose specifications apply	See Pages 11-13 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 45, 52M/F, 53, 54M/F, 55, 58, 61, 65, 66	
Oropharyngeal	Any dose	Sections 59, 60, 62, 63, 64	
	Minimum dose specifications apply	See Page 12-13 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 61, 65, 66	
Waldeyer's Ring (Nasopharyngeal + Oropharyngeal)	Any dose	Sections 42, 46, 47, 48, 49, 50, 51M/F, 59, 60, 62, 63, 64	
	Minimum dose specifications apply	See Page 11-13 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 45, 52M/F, 53, 54M/F, 55, 58, 61, 65, 66	
SPINE:			
Spine (cervical) [Including some or all of the cervical spine (C1 – C7)]	Any dose	Sections 59, 60, 62, 63, 64, 88	
	Minimum dose specifications apply	See Pages 12-13, 18, 25 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 61, 65, 66, 67, 73, 91	
Spine (thoracic) Age at time of XRT: _____ [Including some or all of the thoracic spine (T1 – T12)]	Any dose	Sections 71M/F, 88, 89, 90	
	Minimum dose specifications apply	See Pages 16, 18, 20, 25-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 73, 76, 77, 78, 91	
Spine (lumbar) [Including some or all of the lumbar spine (L1 – L5)]	Any dose	Sections 83F, 84F, 88	
	Minimum dose specifications apply	See Pages 20, 23, 25 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 76, 77, 78, 91	
Spine (sacral) [Including some or all of the sacral spine (S1 – S5)]	Any dose	Sections 82, 83F, 84F, 88	
	Minimum dose specifications apply	See Pages 20, 22-23, 25 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 76, 77, 78, 80, 81, 91	
Spine (whole) [Includes cervical, thoracic, lumbar and sacral spine]	Any dose	Sections 59, 60, 62, 63, 64, 71M/F, 82, 83F, 84F, 88, 89, 90	
	Minimum dose specifications apply	See Pages 12-13, 16, 18, 20, 22-23, 25-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 61, 65, 66, 67, 73, 76, 77, 78, 80, 81, 91	

[§]See instructions on page 2

Radiation by field [§] (mark all that apply)		Applicable guideline sections	
NECK:			
Cervical (neck) Supraclavicular	Any dose	Sections 59, 60, 62, 63, 64, 88	
	Minimum dose specifications apply	See Pages 12-13, 18, 25 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 61, 65, 66, 67, 73, 91	
Mini-Mantle [Includes cervical (neck), supraclavicular, axillary] <i>Excludes mediastinal and lung</i>	Any dose	Sections 59, 60, 62, 63, 64, 69F, 70, 88	
	Minimum dose specifications apply	See Pages 12-15, 18, 25 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 61, 65, 66, 67, 68F, 73, 91	
Mantle [Includes bilateral cervical (neck), supraclavicular, mediastinal, hilar, axillary] Age at time of XRT: _____	Any dose	Sections 59, 60, 62, 63, 64, 69F, 70, 71M/F, 88, 89, 90	
	Minimum dose specifications apply	See Pages 12-16, 18, 25-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 61, 65, 66, 67, 68F, 73, 91	
Extended Mantle [Includes mantle + paraaortic] Age at time of XRT: _____	Any dose	Sections 59, 60, 62, 63, 64, 69F, 70, 71M/F, 79, 88, 89, 90	
	Minimum dose specifications apply	See Pages 12-16, 18-21, 25-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 61, 65, 66, 67, 68F, 73, 74, 75, 76, 77, 78, 91	
Subtotal Lymphoid (STLI) [Includes mantle + paraaortic + spleen] Age at time of XRT: _____	Any dose	Sections 59, 60, 62, 63, 64, 69F, 70, 71M/F, 79, 88, 89, 90	
	Minimum dose specifications apply	See Pages 12-21, 25-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 61, 65, 66, 67, 68F, 72, 73, 74, 75, 76, 77, 78, 91	
Total Lymphoid (TLI) [Includes mantle + inverted Y + spleen] Age at time of XRT: _____	Any dose	Sections 59, 60, 62, 63, 64, 69F, 70, 71M/F, 79, 82, 83F, 84F, 85F, 86M, 88, 89, 90	
	Minimum dose specifications apply	See Pages 12-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 61, 65, 66, 67, 68F, 72, 73, 74, 75, 76, 77, 78, 80, 81, 87M, 91	
AXILLA:			
Axilla Age at time of XRT: _____	Any dose	Sections 69F, 70, 88	
	Minimum dose specifications apply	See Pages 14-15, 25 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 68F, 91	
Mini-Mantle	See "Neck"	See "Neck" (above)	
Mantle	See "Neck"	See "Neck" (above)	
Extended Mantle	See "Neck"	See "Neck" (above)	
Subtotal Lymphoid (STLI)	See "Neck"	See "Neck" (above)	
Total Lymphoid (TLI)	See "Neck"	See "Neck" (above)	
THORAX:			
Chest (thorax): Age at time of XRT: _____ [May include any of the following: mediastinal, hilar, whole lung, chest wall]	Any dose	Sections 62, 63, 64, 69F, 70, 71M/F, 88, 89, 90	
	Minimum dose specifications apply	See Pages 13-16, 18, 25-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 65, 66, 67, 68F, 73, 91	
Whole lung	Any dose	Sections 62, 63, 64, 69F, 70, 71M/F, 88, 89, 90	

[§]See instructions on page 2

Radiation by field [§] (mark all that apply)		Applicable guideline sections
THORAX (cont):		
Mediastinal Age at time of XRT: _____ [Includes mediastinum plus bilateral hilar]	Any dose	Sections 62, 63, 64, 69F, 70, 71M/F, 88, 89, 90
	Minimum dose specifications apply	See Pages 13-16, 18, 25-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 65, 66, 67, 68F, 73, 91
Mini-Mantle	See "Neck"	See "Neck" (page 4)
Mantle	See "Neck"	See "Neck" (page 4)
Extended Mantle	See "Neck"	See "Neck" (page 4)
Subtotal Lymphoid (STLI)	See "Neck"	See "Neck" (page 4)
Total Lymphoid (TLI)	See "Neck"	See "Neck" (page 4)
ABDOMEN:		
Any abdominal field* Age at time of XRT: _____ *Includes: Hepatic, renal, upper quadrant (right, left), spleen (partial, entire), paraaortic, flank/hemiabdomen (right, left)	Any dose	Sections 71M/F, 79, 88, 89, 90
	Minimum dose specifications apply	See Pages 16-21, 25-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 72 (if spleen in field*), 73, 74, 75, 76, 77, 78, 91 *includes left upper quadrant, entire spleen, left flank/hemiabdomen, and paraaortic if spleen in field
Extended mantle	See "Neck"	See "Neck" (page 4)
Subtotal Lymphoid (STLI)	See "Neck"	See "Neck" (page 4)
Total Lymphoid (TLI)	See "Neck"	See "Neck" (page 4)
Inverted Y [Includes paraaortic and pelvic ± spleen]	Any dose	Sections 71 M/F, 79, 82, 83F, 84F, 85F, 86M, 88, 89, 90
	Minimum dose specifications apply	See Pages 16-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 72 (if spleen in field), 73, 74, 75, 76, 77, 78, 80, 81, 87M, 91
Whole abdomen Age at time of XRT: _____ [Includes all abdominal and pelvic fields]	Any dose	Sections 71M/F, 79, 82, 83F, 84F, 85F, 86M, 88, 89, 90
	Minimum dose specifications apply	See Pages 16-26 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 72, 73, 74, 75, 76, 77, 78, 80, 81, 87M, 91
PELVIS:		
Any pelvic field** **Iliac crest to 3 cm below ischium. Includes: Pelvic, vaginal, prostate, bladder, iliac, inguinal, femoral; Flank/hemiabdomen included only if field extended below iliac crest	Any dose	Sections 82 (except femoral), 83F (except iliac/inguinal/femoral), 84F (except inguinal/femoral), 85F (except inguinal/femoral), 86M, 88
	Minimum dose specifications apply	See Pages 20, 22 (except femoral), 23 (except prostate/inguinal/femoral), 24 (except vaginal), and 25 of the Radiation Reference Guide to determine the applicability of the following sections for this patient: Sections 76, 77, 78, 80 (except femoral), 81 (except femoral), 87M, 91
Inverted Y	See "Abdomen"	See "Abdomen" (above)
Whole abdomen	See "Abdomen"	See "Abdomen" (above)
Total Lymphoid (TLI)	See "Neck"	See "Neck" (page 4)
TESTICULAR:		
Testicular	Any dose	Section 86M
	Minimum dose specifications apply	See Page 24 of the Radiation Reference Guide to determine the applicability of the following section for this patient: Section 87M
EXTREMITIES:		
Extremity (Upper, Lower)	Any dose	Section 88
	Minimum dose specifications apply	See Page 25 of the Radiation Reference Guide to determine the applicability of the following section for this patient: Section 91

[§]See instructions on page 2

HEMATOPOIETIC CELL TRANSPLANT: Yes No *If yes:* Sections 92, 93M/F, 94-97
If yes, does patient have any history of **chronic graft-versus-host disease (cGVHD)**? Yes No *If yes:* Sections 98-106*
 *103 – active cGVHD only
 105F – females only

SURGERY: Yes No *If yes*, include applicable guideline sections below:

Surgical procedure (mark if patient received) ↓	Applicable guideline sections
Amputation	Section 107
Central venous catheter	Section 108
Cystectomy	Sections 109, 126, 127, 128M/F, 129M
Enucleation	Section 110
Hysterectomy	Section 111F (see also oophorectomy, if applicable, section 123F or 124F)
Laparotomy	Section 112
Limb sparing procedure	Section 113
Nephrectomy	Section 114M/F
Neurosurgery - brain	Sections 115, 116, 117, 118
Neurosurgery - spinal cord	Sections 119, 120, 121M/F
Oophoropexy	Section 122F
Oophorectomy - unilateral	Section 123F
Oophorectomy - bilateral	Section 124F
Orchiectomy	Section 125M
Pelvic surgery	Sections 126, 127, 128M/F, 129M
Pulmonary lobectomy, metastasectomy and/or wedge resection	Section 130
Splenectomy	Section 131
Thyroidectomy	Section 132

OTHER THERAPEUTIC MODALITIES: Yes No *If yes*, include applicable guideline sections below:

Other Therapeutic Modality (mark if patient received) ↓	Applicable guideline sections
Radioiodine therapy (I-131 thyroid ablation)	Sections 133, 134
Systemic MIBG (in therapeutic doses)	Section 135
Bioimmunotherapy	Section 136

CANCER SCREENING GUIDELINES

Patient type	Cancer type	Age at first screening	Applicable guideline sections (mark as indicated) ↓
All patients	Colorectal	Standard risk: Age 50 years Highest risk: XRT: Age 35 or 10 years after XRT (whichever occurs last) HNPCC: Puberty FAP: Age 21 years IBD: 8 years after diagnosis	Section 139
	Lung	Highest risk: At entry into LTFU	Section 141
	Oral	Highest risk: At entry into LTFU	Section 142
	Skin	Highest risk: At entry into LTFU	Section 144

CANCER SCREENING GUIDELINES (cont)			
Females	Breast	Standard risk: Age 20 years Highest risk: At puberty	Section 137F
	Cervical	All females: 3 years after first vaginal intercourse, or age at 21, whichever occurs first	Section 138F
	Endometrial	Highest risk: Age 35 years	Section 140F
Males	Prostate	Males \geq 45 years (see guideline)	Section 143M
	Testicular	N/A (see guideline)	Section 145M

GENERAL HEALTH SCREENING		
All patients	<input checked="" type="checkbox"/>	Section 146